<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03564756</url>
  </required_header>
  <id_info>
    <org_study_id>AAA-001</org_study_id>
    <nct_id>NCT03564756</nct_id>
  </id_info>
  <brief_title>Effect of Ascorbic Acid Supplementation in Pregnancy on Anemia (AAA)</brief_title>
  <acronym>AAA</acronym>
  <official_title>Effect of Ascorbic Acid Supplementation in Pregnancy on Anemia (AAA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fetal Medicine Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wright State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Five Rivers Health Centers</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fetal Medicine Foundation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A. Anemia is a common problem affecting pregnancy and can result in profound consequences to&#xD;
      both the mother and the growing fetus. Current treatment usually includes administration of&#xD;
      oral or IV iron, or blood transfusions. Vitamin C is known to affect iron metabolism and has&#xD;
      been shown to improve outcomes when used in addition to iron, however, few studies have been&#xD;
      performed in pregnancy. The primary aim of this study is to identify the effects of vitamin C&#xD;
      on anemia in pregnancy. The Investigators propose a double-blind, randomized placebo&#xD;
      controlled trial of 1000mg vitamin C supplementation in 200 low risk pregnancies with&#xD;
      iron-deficiency anemia. All newly enrolled patients, who meet inclusion and exclusion&#xD;
      criteria, will receive the standard of care evaluation and treatment for anemia in pregnancy.&#xD;
      Additionally, patients will be randomized to receive either placebo or vitamin C and&#xD;
      compliance monitored with a pill diary. Data will be analyzed by T tests and Mann-Whitney U&#xD;
      test. If the data shows a positive statistical significance, vitamin C may be a useful&#xD;
      supplement to iron in treating anemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A. Anemia is the most common hematological abnormality during pregnancy and was found to&#xD;
      affect 24.1% of pregnant women in a WHO study.2 The most common types of anemia affecting&#xD;
      pregnancy are iron-deficiency and acute blood loss. Vitamin C, also known as ascorbic acid,&#xD;
      has been well documented to play an active role in the absorption and metabolism of iron from&#xD;
      the gut.6 Vitamin C has been used in studies to treat anemic non-pregnant women resulting in&#xD;
      significant increases in hemoglobin levels. Similar effects have been found in multiple&#xD;
      studies using vitamin C as adjunct treatment for hemodialysis patients with non-responsive&#xD;
      anemia.10,12 Vitamin C has already been extensively studied in pregnant women for its effects&#xD;
      on preeclampsia, preterm birth, neonatal morbidity and other outcomes, and found to have no&#xD;
      adverse effects in doses as high as 1000mg daily or in combination with other medications.8&#xD;
      After an extensive literature search, very few studies have been performed assessing the&#xD;
      effect on hemoglobin levels after vitamin C supplementation. One study by Sharma et al.&#xD;
      supplemented pregnant women with 500mg vitamin C and found a 18.04% increase in hemoglobin&#xD;
      compared to 5.49% in the control.11 A Cochran Review of 29 studies did not discuss or&#xD;
      evaluate the effects of vitamin C on anemia.8 Due to the minimal side-effect profile and&#xD;
      potential benefits of successfully treating anemia, further research in the area is needed.&#xD;
&#xD;
      V. SPECIFIC AIMS OR OBJECTIVES A. To perform a double-blinded, randomized placebo controlled&#xD;
      trial of 1000mg vitamin c supplementation on iron-deficiency anemia in low-risk pregnancies.&#xD;
&#xD;
      VI. SIGNIFICANCE TO PATIENT, INSTITUTION, PROFESSION, OR ALL A. Anemia has been associated&#xD;
      with adverse maternal and fetal outcomes, to include, but not limited to low birth weight,&#xD;
      preterm delivery, perinatal mortality and postpartum depression.1 Per ACOG guidelines, all&#xD;
      pregnant women should be screened for anemia, evaluated for causes and provided supplemental&#xD;
      iron. A study by Sharma et al has already demonstrated a significant increase in hemoglobin&#xD;
      levels in pregnancy with 500mg vitamin C supplementation.11 Due to the paucity of research of&#xD;
      vitamin C in pregnancy, further studies are needed to determine reproducibility.&#xD;
&#xD;
      VII. METHODS A. The investigators plan to enroll 200 patients total, 100 per arm. Potential&#xD;
      subjects will be screened by study personal from the new intakes for prenatal care in the&#xD;
      Five Rivers Center for Women's Health. A complete blood count (CBC) is obtained as standard&#xD;
      of care at the first prenatal visit. The CBC includes hemoglobin level, hematocrit, and red&#xD;
      blood cell indices (i.e. MCV and MCH). Pregnant women in the first half of their pregnancy&#xD;
      who are found to have a hematocrit level less than 33% (Caucasian and other races), and less&#xD;
      than 31% (African American women), will be potentially eligible for enrollment. Women who are&#xD;
      noted to be anemic per these thresholds will have iron studies (iron, transferrin, ferritin)&#xD;
      and hemoglobin electrophoresis (if not already performed), as part of the standard of care&#xD;
      for the evaluation of anemia during pregnancy.1 Inclusion criteria consists of gestational&#xD;
      age at enrollment less than 20 0/7 weeks, singleton gestation, iron deficiency anemia defined&#xD;
      as maternal serum ferritin levels less than 15 micrograms/dL, and planned delivery at Miami&#xD;
      Valley Hospital. Exclusion criteria consist of vitamin C use &gt;150mg/day (typical prenatal&#xD;
      vitamin contains 60mg Vitamin C), diabetes (gestational, types 1,2); chronic medical disease;&#xD;
      known or discovered hemoglobinopathy (including heterozygous states); known metabolic disease&#xD;
      that may contribute to impaired iron absorption (including a history of bariatric surgery,&#xD;
      renal disease and an inability to tolerate oral iron); known fetal abnormalities;&#xD;
      participation in another interventional trial; illicit drug or alcohol use. All&#xD;
      risks/benefits will be reviewed and all questions answered prior to the patient being&#xD;
      enrolled. Written informed consent will be obtained by a study investigator or qualified&#xD;
      personnel. Gestational dating will be based upon the best obstetrical estimate.&#xD;
&#xD;
      B. A compounding pharmacy will make 30,000 placebo capsules containing an inert substance&#xD;
      (i.e. silica based cellulose), identical appearing to 30,000 capsules of 500mg vitamin C. The&#xD;
      pharmacy will package 300 pills of either placebo or vitamin C into 200 boxes, labeled only&#xD;
      with the project name and a number. A key containing the known substance of each box and&#xD;
      number will be kept by the pharmacy until the end of the study. The boxes will be stored in a&#xD;
      secured area of the principal investigators office. The boxes will be taken to Five Rivers&#xD;
      Women's Health Clinic to be distributed to enrolled patients. Once enrolled, patients will be&#xD;
      given a random box and instructed to take 1 pill twice daily. Patients will be instructed to&#xD;
      record pill usage daily for compliance. The patient's name and assigned box number will be&#xD;
      kept in a locked cabinet. At the end of the study, the two keys will be compared to determine&#xD;
      who received placebo or vitamin C. Both groups will receive prescriptions for ferrous&#xD;
      sulfate, 65mg taken once daily; docusate sodium to be taken as needed for constipation; and&#xD;
      prenatal vitamins once daily. Patients will receive follow up labs as part of the standard of&#xD;
      care for anemia, to include at 28 week, and at delivery. All data will be collected in an&#xD;
      Excel spreadsheet, with patient identifiers removed. Data will be analyzed by applying basic&#xD;
      T tests and the Mann-Whitney-U test to determine the changes in lab values of hemoglobin,&#xD;
      hematocrit, iron, transferrin, ferritin between experimental and control before and after&#xD;
      treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">August 1, 2019</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized Parallel Group, Placebo Controlled Trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Double blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in serum hemoglobin</measure>
    <time_frame>To be measured at 1st prenatal visit, 28 weeks', and at delivery</time_frame>
    <description>Change in serum hemoglobin</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Anemia in Pregnancy</condition>
  <arm_group>
    <arm_group_label>Iron + Vitamin C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One iron tablet once a day plus a 500 mg vitamin C tablet twice a day until delivery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Iron + Placebo</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>One iron tablet once a day plus a placebo tablet twice a day until delivery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin C</intervention_name>
    <description>1000mg Vitamin C per day</description>
    <arm_group_label>Iron + Vitamin C</arm_group_label>
    <other_name>Ascorbic Acid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  gestational age at enrollment less than 20 0/7 weeks,&#xD;
&#xD;
          -  singleton gestation,&#xD;
&#xD;
          -  iron deficiency anemia defined as maternal serum ferritin levels less than 15&#xD;
             micrograms/dL, and&#xD;
&#xD;
          -  planned delivery at Miami Valley Hospital.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  vitamin C use &gt;150mg/day (typical prenatal vitamin contains 60mg Vitamin C),&#xD;
&#xD;
          -  diabetes (gestational, types 1,2); chronic medical disease;&#xD;
&#xD;
          -  known or discovered hemoglobinopathy (including heterozygous states);&#xD;
&#xD;
          -  known metabolic disease that may contribute to impaired iron absorption (including a&#xD;
             history of bariatric surgery, renal disease and an inability to tolerate oral iron);&#xD;
&#xD;
          -  known fetal abnormalities;&#xD;
&#xD;
          -  participation in another interventional trial;&#xD;
&#xD;
          -  illicit drug or alcohol use&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Pregnant women</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>David McKenna, MD</last_name>
    <phone>937-208-5696</phone>
    <email>dsmckenna@premierhealth.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kaye Snow</last_name>
    <phone>937-208-2411</phone>
    <email>eksnow@premierhealth.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Five Rivers Health Centers</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45409</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David McKenna, MD</last_name>
      <phone>937-208-5696</phone>
      <email>dsmckenna@premierhealth.com</email>
    </contact>
    <contact_backup>
      <last_name>Kaye Snow</last_name>
      <phone>937-208-2411</phone>
      <email>eksnow@premierhealth.com</email>
    </contact_backup>
    <investigator>
      <last_name>David McKenna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zoe Gauthier, DO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Keshia Torres-Shafer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 95: anemia in pregnancy. Obstet Gynecol. 2008 Jul;112(1):201-7. doi: 10.1097/AOG.0b013e3181809c0d. Erratum in: Obstet Gynecol. 2020 Jan;135(1):222.</citation>
    <PMID>18591330</PMID>
  </reference>
  <reference>
    <citation>McLean E, Cogswell M, Egli I, Wojdyla D, de Benoist B. Worldwide prevalence of anaemia, WHO Vitamin and Mineral Nutrition Information System, 1993-2005. Public Health Nutr. 2009 Apr;12(4):444-54. doi: 10.1017/S1368980008002401. Epub 2008 May 23.</citation>
    <PMID>18498676</PMID>
  </reference>
  <reference>
    <citation>Abdel Moety GAF, Ali AM, Fouad R, Ramadan W, Belal DS, Haggag HM. Amino acid chelated iron versus an iron salt in the treatment of iron deficiency anemia with pregnancy: A randomized controlled study. Eur J Obstet Gynecol Reprod Biol. 2017 Mar;210:242-246. doi: 10.1016/j.ejogrb.2017.01.003. Epub 2017 Jan 3.</citation>
    <PMID>28073037</PMID>
  </reference>
  <reference>
    <citation>Hanieh S, Ha TT, Simpson JA, Braat S, Thuy TT, Tran TD, King J, Tuan T, Fisher J, Biggs BA. Effect of low-dose versus higher-dose antenatal iron supplementation on child health outcomes at 36 months of age in Viet Nam: longitudinal follow-up of a cluster randomised controlled trial. BMJ Glob Health. 2017 Sep 22;2(3):e000368. doi: 10.1136/bmjgh-2017-000368. eCollection 2017.</citation>
    <PMID>29018582</PMID>
  </reference>
  <reference>
    <citation>Joseph B, Ramesh N. Weekly dose of Iron-Folate Supplementation with Vitamin-C in the workplace can prevent anaemia in women employees. Pak J Med Sci. 2013 Jan;29(1):47-52. doi: 10.12669/pjms.291.3016.</citation>
    <PMID>24353506</PMID>
  </reference>
  <reference>
    <citation>Lane DJ, Richardson DR. The active role of vitamin C in mammalian iron metabolism: much more than just enhanced iron absorption! Free Radic Biol Med. 2014 Oct;75:69-83. doi: 10.1016/j.freeradbiomed.2014.07.007. Epub 2014 Jul 15. Review.</citation>
    <PMID>25048971</PMID>
  </reference>
  <reference>
    <citation>Rumbold A, Crowther CA. Vitamin C supplementation in pregnancy. Cochrane Database Syst Rev. 2005 Apr 18;(2):CD004072. Review. Update in: Cochrane Database Syst Rev. 2015;9:CD004072.</citation>
    <PMID>15846696</PMID>
  </reference>
  <reference>
    <citation>Pe√±a-Rosas JP, De-Regil LM, Gomez Malave H, Flores-Urrutia MC, Dowswell T. Intermittent oral iron supplementation during pregnancy. Cochrane Database Syst Rev. 2015 Oct 19;(10):CD009997. doi: 10.1002/14651858.CD009997.pub2. Review.</citation>
    <PMID>26482110</PMID>
  </reference>
  <reference>
    <citation>Sedighi O, Makhlough A, Janbabai G, Neemi M. Comparative study of intravenous iron versus intravenous ascorbic Acid for treatment of functional iron deficiency in patients under hemodialysis: a randomized clinical trial. Nephrourol Mon. 2013 Sep;5(4):913-7. doi: 10.5812/numonthly.12038. Epub 2013 Jul 24.</citation>
    <PMID>24350091</PMID>
  </reference>
  <reference>
    <citation>Sultana T, DeVita MV, Michelis MF. Oral vitamin C supplementation reduces erythropoietin requirement in hemodialysis patients with functional iron deficiency. Int Urol Nephrol. 2016 Sep;48(9):1519-24. doi: 10.1007/s11255-016-1309-9. Epub 2016 May 11.</citation>
    <PMID>27170339</PMID>
  </reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>May 25, 2018</study_first_submitted>
  <study_first_submitted_qc>June 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2018</study_first_posted>
  <last_update_submitted>August 7, 2019</last_update_submitted>
  <last_update_submitted_qc>August 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fetal Medicine Foundation</investigator_affiliation>
    <investigator_full_name>David S. McKenna</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Anemia</keyword>
  <keyword>Pregnancy</keyword>
  <keyword>Iron</keyword>
  <keyword>Vitamin C</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascorbic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Data will be used by the study team to test the study hypothesis</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

